Skip to main content
Top
Published in: Diagnostic Pathology 1/2018

Open Access 01-12-2018 | Research

Tissue expression of retinoic acid receptor alpha and CRABP2 in metastatic nephroblastomas

Authors: Ana Paula Percicote, Gabriel Lazaretti Mardegan, Elizabeth Schneider Gugelmim, Sergio Ossamu Ioshii, Ana Paula Kuczynski, Seigo Nagashima, Lúcia de Noronha

Published in: Diagnostic Pathology | Issue 1/2018

Login to get access

Abstract

Background

Nephroblastoma or Wilms tumor is the most frequent kidney cancer in children and accounts for 98% of kidney tumors in this age group. Despite favorable prognosis, a subgroup of these patients progresses to recurrence and death. The retinoic acid (RA) pathway plays a role in the chemoprevention and treatment of tumors due to its effects on cell differentiation and its antiproliferative, anti-oxidant, and pro-apoptotic activities. Reports describe abnormal cellular retinoic acid-binding protein 2 (CRABP2) expression in neoplasms and its correlation with prognostic factors and clinical and pathological characteristics. The aim of this study was to evaluate the immunohistochemical expression of retinoic acid receptor alpha (RARA) and CRABP2 in paraffin-embedded samples of nephroblastomas via semiquantitative and quantitative analyses and to correlate this expression with prognostic factors.

Methods

Seventy-seven cases of nephroblastomas were selected from pediatric oncology services. The respective medical records and surgical specimens were reviewed. Three representative tumor samples and one non-tumor renal tissue sample were selected for the preparation of tissue microarrays (TMA). The Allred scoring system was used for semiquantitative immunohistochemical analyses, whereas a morphometric analysis of the stained area was employed for quantitative evaluation. The nonparametric Mann-Whitney test was used for comparisons between two groups, while the nonparametric Kruskal-Wallis test was used to compare three or more groups.

Results

Immunopositivity for RARA and CRABP2 was observed in both the nucleus and cytoplasm. All histological components of the nephroblastoma (blastema, epithelium, and stroma) were positive for both markers. RARA, based on semiquantitative analyses, and CRABP2, bases on quantitative analyses, exhibited increased immunohistochemical expression in patients with metastasis, with p values of 0.0247 and 0.0128, respectively. These findings were similar to the results of the quantitative analysis of RARA expression, showing greater immunopositivity in tumor samples of patients subjected to pre-surgical chemotherapy. No significant correlation was found with the other variables studied, such as disease stage, anaplasia, risk group, histological type, nodal involvement, and clinical evolution.

Conclusions

Semiquantitative and quantitative analyses of the markers RARA and CRABP2 indicate their potential as biomarkers for tumor progression and their participation in nephroblastoma tumorigenesis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Stiller CA, Parkin DM. Geographic and ethnic variations in the incidence of childhood cancer. Br Med Bull. 1996;52(4):682–703.CrossRefPubMed Stiller CA, Parkin DM. Geographic and ethnic variations in the incidence of childhood cancer. Br Med Bull. 1996;52(4):682–703.CrossRefPubMed
2.
go back to reference Maschietto M, Trapé AP, Piccoli FS, Ricca TI, Dias AAM, Coudry RA, Galante PA, Torres C, Fahhan L, Lourenço S, Grundy PE, Camargo B, Souza S, Neves EJ, Soares FA, Brentani H, Carraro DM. Temporal blastemal cell gene expression analysis in the kidney reveals new Wnt and related signaling pathway genes to be essential for Wilms´ tumor onset. Cell Death Dis. 2011;2:e224.CrossRefPubMedPubMedCentral Maschietto M, Trapé AP, Piccoli FS, Ricca TI, Dias AAM, Coudry RA, Galante PA, Torres C, Fahhan L, Lourenço S, Grundy PE, Camargo B, Souza S, Neves EJ, Soares FA, Brentani H, Carraro DM. Temporal blastemal cell gene expression analysis in the kidney reveals new Wnt and related signaling pathway genes to be essential for Wilms´ tumor onset. Cell Death Dis. 2011;2:e224.CrossRefPubMedPubMedCentral
3.
go back to reference Pritchard-Jones K, Moroz V, Vujanic G, Powis M, Walker J, Messahel B, Hobson R, Levitt G, Kelsey A, Mitchell C. Treatment and outcome of Wilms’tumour patients: an analysis of all cases registered in the UKW3 trial. Ann Oncol. 2012;23(9):2457–63.CrossRefPubMed Pritchard-Jones K, Moroz V, Vujanic G, Powis M, Walker J, Messahel B, Hobson R, Levitt G, Kelsey A, Mitchell C. Treatment and outcome of Wilms’tumour patients: an analysis of all cases registered in the UKW3 trial. Ann Oncol. 2012;23(9):2457–63.CrossRefPubMed
4.
go back to reference Honeyman JN, Rich BS, Mcevoy MP, Knowles MA, Heller G, Riachy E, Kobos R, Shukla N, Wolden SL, Steinherz PG, La Quaglia MP. Factors associated with relapse and survival in Wilms tumor: a multivariate analysis. J Pediatr Surg. 2012;47(6):1228–33.CrossRefPubMed Honeyman JN, Rich BS, Mcevoy MP, Knowles MA, Heller G, Riachy E, Kobos R, Shukla N, Wolden SL, Steinherz PG, La Quaglia MP. Factors associated with relapse and survival in Wilms tumor: a multivariate analysis. J Pediatr Surg. 2012;47(6):1228–33.CrossRefPubMed
5.
go back to reference Dome JS, Graf N, Geller JI, Fernandez CV, Mullen EA, Spreafico F, Van Den Heuvel-Eibrink M, Pritchard-Jones K. Advances in Wilms tumor treatment and biology: progress through international collaboration. J Clin Oncol. 2015;33(27):2999–3007.CrossRefPubMedPubMedCentral Dome JS, Graf N, Geller JI, Fernandez CV, Mullen EA, Spreafico F, Van Den Heuvel-Eibrink M, Pritchard-Jones K. Advances in Wilms tumor treatment and biology: progress through international collaboration. J Clin Oncol. 2015;33(27):2999–3007.CrossRefPubMedPubMedCentral
6.
go back to reference Zirn B, Hartmann O, Samans B, Krause M, Wittmann S, Mertens F, Graf N, Eilers M, Gessler M. Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters. Int J Cancer. 2006;118(8):1954–62.CrossRefPubMed Zirn B, Hartmann O, Samans B, Krause M, Wittmann S, Mertens F, Graf N, Eilers M, Gessler M. Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters. Int J Cancer. 2006;118(8):1954–62.CrossRefPubMed
7.
go back to reference Wegert J, Bausenwein S, Kneitz S, Roth S, Graf N, Geissnger E, Gessler M. Retinoic acid pathway activity in Wilms tumors and chacarecterization of biological responses in vitro. Mol Cancer. 2011;10:136.CrossRefPubMedPubMedCentral Wegert J, Bausenwein S, Kneitz S, Roth S, Graf N, Geissnger E, Gessler M. Retinoic acid pathway activity in Wilms tumors and chacarecterization of biological responses in vitro. Mol Cancer. 2011;10:136.CrossRefPubMedPubMedCentral
8.
go back to reference Theodosiou M, Laudet V, Schubert M. From carrot to clinic: an overview of the retinoic acid signaling pathway. Cell Mol Life Sci. 2010;67(9):1423–45.CrossRefPubMed Theodosiou M, Laudet V, Schubert M. From carrot to clinic: an overview of the retinoic acid signaling pathway. Cell Mol Life Sci. 2010;67(9):1423–45.CrossRefPubMed
9.
go back to reference Passeri D, Doldo E, Tarquini C, Costanza G, Mazzaglia D, Agostinelli S, Campione E, Di Stefani A, Giunta A, Bianchi L, Orlandi A. Loss of CRABP-II characterizes human skin poorly diferrenciated squamous cell carcinomas and favors DMBA/TPA-induced carcinogenesis. J Invest Dermatol. 2016;136(6):1255–66.CrossRefPubMed Passeri D, Doldo E, Tarquini C, Costanza G, Mazzaglia D, Agostinelli S, Campione E, Di Stefani A, Giunta A, Bianchi L, Orlandi A. Loss of CRABP-II characterizes human skin poorly diferrenciated squamous cell carcinomas and favors DMBA/TPA-induced carcinogenesis. J Invest Dermatol. 2016;136(6):1255–66.CrossRefPubMed
10.
go back to reference Gupta S, Pramanik D, Mukherjee R, Campbell NR, Elumalai S, Wilde RF, Hong S, Goggins MG, Jesus-Acosta A, Laheru D, Maitra A. Molecular determinants of retinoic acid sensitivity in pancreatic cancer. Clin Cancer Res. 2012;18(1):280–9.CrossRefPubMed Gupta S, Pramanik D, Mukherjee R, Campbell NR, Elumalai S, Wilde RF, Hong S, Goggins MG, Jesus-Acosta A, Laheru D, Maitra A. Molecular determinants of retinoic acid sensitivity in pancreatic cancer. Clin Cancer Res. 2012;18(1):280–9.CrossRefPubMed
12.
go back to reference Favorskaya I, Kainov Y, Chemeris G, Komelkov A, Zborovskaya I, Tchevkina E. Expression and clinical significance of CRABP1 and CRABP2 in non-small cell lung cancer. Tumour Biol. 2014;35(10):10295–300.CrossRefPubMed Favorskaya I, Kainov Y, Chemeris G, Komelkov A, Zborovskaya I, Tchevkina E. Expression and clinical significance of CRABP1 and CRABP2 in non-small cell lung cancer. Tumour Biol. 2014;35(10):10295–300.CrossRefPubMed
14.
go back to reference Li W, Kessler P, Williams BRG. Transcript profiling of Wilms tumors reveals connections to kidney morphogenesis and expression patterns associated with anaplasia. Oncogene. 2005;24(3):457–68.CrossRefPubMed Li W, Kessler P, Williams BRG. Transcript profiling of Wilms tumors reveals connections to kidney morphogenesis and expression patterns associated with anaplasia. Oncogene. 2005;24(3):457–68.CrossRefPubMed
15.
go back to reference Zirn B, Samans B, Spangenberg C, Graf N, Eilers M, Gessler M. All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo. Oncogene. 2005;24(3):5246–51.CrossRefPubMed Zirn B, Samans B, Spangenberg C, Graf N, Eilers M, Gessler M. All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo. Oncogene. 2005;24(3):5246–51.CrossRefPubMed
16.
go back to reference Gupta A, Kessler P, Rawwas J, Williams BRG. Regulation of CRABP-II expression by MycN in Wilms tumor. Exp Cell Res. 2008;314(20):3663–8.CrossRefPubMed Gupta A, Kessler P, Rawwas J, Williams BRG. Regulation of CRABP-II expression by MycN in Wilms tumor. Exp Cell Res. 2008;314(20):3663–8.CrossRefPubMed
17.
go back to reference Chong DC, Raboni SM, Abujamra KB, Marani DM, Nogueira MB, Tsuchiya LRV, Neto HJC, Flizikowski FBZ, Noronha L. Respiratory viruses in pediatric necropsies: an immunohistochemical study. Pediatr Dev Pathol. 2009;12(3):211–6.CrossRefPubMed Chong DC, Raboni SM, Abujamra KB, Marani DM, Nogueira MB, Tsuchiya LRV, Neto HJC, Flizikowski FBZ, Noronha L. Respiratory viruses in pediatric necropsies: an immunohistochemical study. Pediatr Dev Pathol. 2009;12(3):211–6.CrossRefPubMed
18.
go back to reference Harvey J, Clark G, Osborne C, Allred D. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17(5):1474–81.CrossRefPubMed Harvey J, Clark G, Osborne C, Allred D. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17(5):1474–81.CrossRefPubMed
19.
go back to reference Simões MA, Pabis FC, Freitas AKE, Azevedo MLVA, Ronchi DCM. Immunoexpression of GADD45β in the myocardium of newborns experiencing perinatal hypoxia. Pathol Res Pract. 2017;213(3):222–6.CrossRefPubMed Simões MA, Pabis FC, Freitas AKE, Azevedo MLVA, Ronchi DCM. Immunoexpression of GADD45β in the myocardium of newborns experiencing perinatal hypoxia. Pathol Res Pract. 2017;213(3):222–6.CrossRefPubMed
20.
21.
go back to reference Wang H, Yang R, Zhong L, Zhu XY, Ma PP, Yang XQ, Jiang KL, Liu BZ. Location of NLS-RARα protein in NB4 cell and nude mice. Oncol Lett. 2017;13(4):2045–52.CrossRefPubMedPubMedCentral Wang H, Yang R, Zhong L, Zhu XY, Ma PP, Yang XQ, Jiang KL, Liu BZ. Location of NLS-RARα protein in NB4 cell and nude mice. Oncol Lett. 2017;13(4):2045–52.CrossRefPubMedPubMedCentral
22.
go back to reference Goto E, Tomita A, Hayakawa F, Atsumi A, Kiyoi H, Naoe T. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood. 2011;118(6):1600–9.CrossRefPubMed Goto E, Tomita A, Hayakawa F, Atsumi A, Kiyoi H, Naoe T. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood. 2011;118(6):1600–9.CrossRefPubMed
23.
go back to reference Napoli JL. Biochemical pathways of retinoid transport, metabolism and signal transduction. Clin Immunol Immunopathol. 1996;80(3):S52–62.CrossRefPubMed Napoli JL. Biochemical pathways of retinoid transport, metabolism and signal transduction. Clin Immunol Immunopathol. 1996;80(3):S52–62.CrossRefPubMed
24.
go back to reference Vreeland A, Yu S, Levi L, Rosseto DB, Noy N. Transcript stabilization by the RNA-binding protein HuR is regulated by cellular retinoic acid-binding protein 2. Mol Cell Biol. 2014;34(12):2135–46.CrossRefPubMedPubMedCentral Vreeland A, Yu S, Levi L, Rosseto DB, Noy N. Transcript stabilization by the RNA-binding protein HuR is regulated by cellular retinoic acid-binding protein 2. Mol Cell Biol. 2014;34(12):2135–46.CrossRefPubMedPubMedCentral
25.
go back to reference Liebler S, Überschär B, Kübert H, Brems S, Schnitger A, Tsukada M, Zouboulis CC, Ritz E, Wagner J. The renal retinoid system: time-dependent activation in experimental glomerulonephritis. Am J Physiol Renal Physiol. 2004;286(3):F458–65.CrossRefPubMed Liebler S, Überschär B, Kübert H, Brems S, Schnitger A, Tsukada M, Zouboulis CC, Ritz E, Wagner J. The renal retinoid system: time-dependent activation in experimental glomerulonephritis. Am J Physiol Renal Physiol. 2004;286(3):F458–65.CrossRefPubMed
Metadata
Title
Tissue expression of retinoic acid receptor alpha and CRABP2 in metastatic nephroblastomas
Authors
Ana Paula Percicote
Gabriel Lazaretti Mardegan
Elizabeth Schneider Gugelmim
Sergio Ossamu Ioshii
Ana Paula Kuczynski
Seigo Nagashima
Lúcia de Noronha
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2018
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-018-0686-z

Other articles of this Issue 1/2018

Diagnostic Pathology 1/2018 Go to the issue